Published in J Infect Dis on July 01, 1999
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis (2006) 2.01
Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother (2004) 1.69
Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother (2003) 1.59
Vaginal drug delivery systems for HIV prevention. AAPS J (2009) 1.51
Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother (2000) 1.49
Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res (2009) 1.30
Amyloid-binding small molecules efficiently block SEVI (semen-derived enhancer of virus infection)- and semen-mediated enhancement of HIV-1 infection. J Biol Chem (2010) 1.26
A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS PharmSciTech (2008) 1.08
Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob Agents Chemother (2005) 0.97
The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol (2005) 0.95
Polyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infection. PLoS One (2013) 0.86
Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India. AIDS Res Ther (2006) 0.86
An Update on Vaginal Microbicides. Curr Infect Dis Rep (2001) 0.83
Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection. J Antimicrob Chemother (2014) 0.81
The use of preexposure treatments for HIV prophylaxis. HIV AIDS (Auckl) (2012) 0.78
Expression of Human CD4 and chemokine receptors in cotton rat cells confers permissiveness for productive HIV infection. Virol J (2009) 0.77
The Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal Applications. PLoS One (2015) 0.76
The Cholestanol-Conjugated Sulfated Oligosaccharide PG545 Disrupts the Lipid Envelope of Herpes Simplex Virus Particles. Antimicrob Agents Chemother (2015) 0.75
Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet (1999) 24.24
Linkage disequilibrium in the human genome. Nature (2001) 17.24
Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science (1990) 6.77
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med (1998) 6.75
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A (1989) 6.58
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science (1990) 4.43
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr (2000) 3.53
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis (2000) 2.90
Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology (1997) 2.37
T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol (1998) 2.31
Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. Proc Natl Acad Sci U S A (1990) 2.29
Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol (2005) 2.28
The EPIC nutrient database project (ENDB): a first attempt to standardize nutrient databases across the 10 European countries participating in the EPIC study. Eur J Clin Nutr (2007) 2.21
Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis (1989) 2.21
Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis (1982) 2.16
Serologic analysis of first-episode nonprimary genital herpes simplex virus infection. Presence of type 2 antibody in acute serum samples. Am J Med (1984) 2.05
Major antigen-induced domain rearrangements in an antibody. Structure (1993) 1.99
Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother (1996) 1.86
Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology (1995) 1.86
Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics (1996) 1.77
Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis (1987) 1.68
Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J Infect Dis (1986) 1.68
Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs. J Exp Med (1995) 1.63
Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother (2003) 1.59
Allergic reactions to workplace allergens. JAMA (1997) 1.57
The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect (2006) 1.56
Evaluation of a possible association of urban air toxics and asthma. Environ Health Perspect (1995) 1.52
Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc Natl Acad Sci U S A (1993) 1.52
Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother (2000) 1.49
Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy (1999) 1.45
Evaluation of occupational asthma from airborne egg protein exposure in multiple settings. Chest (1990) 1.45
Crystal structure of the principal neutralization site of HIV-1. Science (1994) 1.43
The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latency-associated transcript region. J Exp Med (1996) 1.41
House dust (1-3)-beta-D-glucan and wheezing in infants. Allergy (2007) 1.40
More rapid isolation of herpes simplex virus in a continuous line of mink lung cells than in Vero or human fibroblast cells. Diagn Microbiol Infect Dis (1984) 1.39
Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology (1995) 1.36
Pulmonary and immunologic evaluation of foundry workers exposed to methylene diphenyldiisocyanate (MDI). J Allergy Clin Immunol (1988) 1.29
Mediastinal and supraclavicular lymphadenitis and pneumonitis due to Chlamydia trachomatis serovars L1 and L2. N Engl J Med (1984) 1.25
Macintosh tenodesis for anterolateral instability of the knee. J Bone Joint Surg Br (1980) 1.24
Acceptability of human papillomavirus self testing in female adolescents. Sex Transm Infect (2005) 1.24
Arthroscopy and arthrography of the knee: a critical review. J Bone Joint Surg Br (1980) 1.24
Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology (1997) 1.23
Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis (2001) 1.23
Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis (1997) 1.22
Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis (1993) 1.21
The distribution of vitamins A and A(2). II. Biochem J (1939) 1.20
Recurrent genital herpes simplex virus infection in guinea pigs. Intervirology (1985) 1.20
Clinical and pharmacokinetic evaluation of nafcillin in infants and children. J Pediatr (1978) 1.20
HSV shedding. Antiviral Res (2004) 1.18
Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis (1998) 1.18
Dietary sources and correlates of sodium and potassium intakes in the French general population. Eur J Clin Nutr (2009) 1.18
A combined respiratory and cutaneous hypersensitivity syndrome induced by work exposure to quaternary amines. J Allergy Clin Immunol (1994) 1.17
Varicella-zoster virus infection of strain 2 guinea pigs. J Infect Dis (1985) 1.16
Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120. Biochemistry (1991) 1.16
Herpes simplex virus vaccines. Vaccine (1999) 1.14
Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications. Science (1991) 1.14
Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc (1999) 1.14
Poly(sodium 4-styrene sulfonate): an effective candidate topical antimicrobial for the prevention of sexually transmitted diseases. J Infect Dis (2000) 1.14
Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother (1994) 1.14
The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections. J Infect Dis (1984) 1.13
Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2. Antiviral Res (1999) 1.13
Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis (1995) 1.13
The natural history of adult asthma: what do we know? Ann Allergy Asthma Immunol (2000) 1.10
Zosteriform spread of herpes simplex virus type 2 genital infection in the guinea-pig. J Gen Virol (1986) 1.09
Rubella immunity in older children, teenagers, and young adults: a comparison of immunity in those previously immunized with those unimmunized. J Pediatr (1982) 1.09
Topical microbicides. Current status and research considerations for adolescent girls. Sex Transm Dis (1998) 1.08
Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. J Infect Dis (1994) 1.08
Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res (1988) 1.07
Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. J Gen Virol (1986) 1.06
Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys (1987) 1.05
Detection of IgE-mediated respiratory sensitization in workers exposed to hexahydrophthalic anhydride. J Allergy Clin Immunol (1985) 1.05
Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res (1989) 1.04
Models of intrapartum care and women's trade-offs in remote and rural Scotland: a mixed-methods study. BJOG (2007) 1.03
DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine (1996) 1.03
Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics (1982) 1.03
Indirect assessment of 4,4'-diphenylmethane diisocyanate (MDI) exposure by evaluation of specific humoral immune responses to MDI conjugated to human serum albumin. Am J Ind Med (1998) 1.01
Immune responses in farm workers after exposure to Bacillus thuringiensis pesticides. Environ Health Perspect (1999) 1.01
Poly(sodium 4-styrene sulfonate): evaluation of a topical microbicide gel against herpes simplex virus type 2 and Chlamydia trachomatis infections in mice. Clin Microbiol Infect (2003) 1.00
DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis (1996) 1.00
Activation of the immunoglobulin kappa 3' enhancer in pre-B cells correlates with the suppression of a nuclear factor binding to a sequence flanking the active core. Nucleic Acids Res (1994) 1.00
Golgi-like, transneuronal retrograde labelling with CNS injections of herpes simplex virus type 1. Brain Res Bull (1989) 0.99
Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children. J Virol (1993) 0.99
Varicella in hairless guinea pigs. J Infect Dis (1991) 0.98
Serum-neutralizing antibody to VP4 and VP7 proteins in infants following vaccination with WC3 bovine rotavirus. J Virol (1990) 0.98
Elevation of cyclic AMP in C-1300 murine neuroblastoma by adenosine and related compounds and the antagonism of this response by methylxanthines. Biochem Pharmacol (1977) 0.98
Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis (1999) 0.98
Diisocyanate conjugate and immunoassay characteristics influence detection of specific antibodies in HDI-exposed workers. Clin Exp Allergy (2007) 0.97
Repression of the immunoglobulin heavy chain 3' enhancer by helix-loop-helix protein Id3 via a functionally important E47/E12 binding site: implications for developmental control of enhancer function. Eur J Immunol (1995) 0.97